According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Concomitant administration of these medicinal products is not recommended. Coadministration with tipranavir/ritonavir (500/100 mg twice daily) decreased lopinavir AUC, Cmin and Cmax by 55%, 70% and 47%, respectively.
Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.

Kaletra should not be administered with tipranavir/ritonavir. Co-administration with tipranavir (500 mg twice daily) and ritonavir (200 mg twice daily) is not recommended. Coadministration of tipranavir/ritonavir (500/200 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) to 21 HIV+ subjects decreased lopinavir Cmax, AUC and Cmin by 47%, 55% and 70%, respectively.  Data from 69 subjects showed a 52% decrease in lopinavir Cmin.
Kaletra Prescribing Information, AbbVie Ltd, October 2020.

Coadministration of lopinavir (400/100 mg twice daily) and tipranavir/ritonavir (500/200 mg twice daily) decreased lopinavir Cmax, AUC and Cmin by 47%, 55% and 70%.  The clinical relevance of this reduction in lopinavir concentrations has not been established. The concomitant use of tipranavir, co-administered with low dose ritonavir, with lopinavir/ritonavir is not recommended. If the combination is nevertheless considered necessary, a monitoring of the plasma levels of lopinavir is strongly encouraged.
Aptivus Summary of Product Characteristics, Boehringer Ingelheim Ltd, July 2020.

Combining lopinavir with tipranavir/ritonavir is not recommended. Coadministration of lopinavir/ritonavir (400/100 mg twice daily) with tipranavir/ritonavir (500/200 mg twice daily) to 21 HIV+ subjects resulted in decreases in lopinavir Cmax, AUC and Cmin of 47%, 55% and 70% respectively.
Aptivus Prescribing Information, Boehringer Ingelheim, June 2020.

The effects of lopinavir and ritonavir dose adjustments when given with tipranavir were investigated in 6 HIV+ subjects. Subjects were stable on lopinavir/ritonavir 400/100 mg twice daily; tipranavir 500 mg twice daily was added and the lopinavir/ritonavir adjusted to 400/300 mg or 533/233 mg twice daily. The former dose schedule showed an increase in lopinavir plasma exposure (Ctrough increased from 4.17 to 7.05 µg/ml), consequent to the increased ritonavir dose. Lopinavir plasma concentrations showed a high inter individual variability, suggesting the need for TDM when this combination is used.
Effect of lopinavir and ritonavir dose adjustments on the pharmacokinetic interaction between LPV/RTV and tipranavir. Harris et al. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February, 2006, abstract 584.

Coadministration of lopinavir/ritonavir (400/100 mg twice daily, n=79) with tipranavir/ritonavir (500/100 mg) resulted in a 49, 43 and 55% decrease in lopinavir AUC, Cmax and Cmin, respectively. The clinical relevance of these reductions has not yet been established.
Pharmacokinetics and safety of tipranavir/ritonavir alone or in combination with saquinavir, amprenavir or lopinavir: Interim analysis of BI1182.51. Leith J Walmsley S, Katlama C, et al., 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 2004, abstract 5.1.